• DOI:10.1093/CID/CIS500
• Corpus ID: 16304945

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

@article{Berenguer2012SustainedVR,
  title={Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.},
  author={Juan Berenguer and Elena Rodr{\'i}guez and Pilar Miralles and Miguel Angel von Wichmann and Jos{\'e} L{\'o}pez-Aldeguer and Jos{\'e}p Mallolas and Mar{\'i}a Jos{\'e} Galindo and Eva Van den Eynde and Mar{\'i}a Jes{\'u}s T{\'e}llez and Carmen Quereda and A Sadat Jou and Jos{\'e} Sanz and Carlos Barros and Ignacio de Los Santos and Federico Pulido and Josep Guardiola and Enrique Ortega and Rafael Rubio and Juan Jos{\'e} Jusdado and Mar{\'i}a Luisa Montes and Gabriel Gaspar and Herminia Esteban and Jos{\'e} Mar{\'i}a Bell{\'o}n and Juan Juli{\'a}n Gonz{\'a}lez-Garc{\'i}a},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2012},
  volume={55 5},
  pages={
          728-36
        }
}

• J. Berenguer, Elena Rodríguez, +21 authors J. González-García
• Published 1 September 2012
• Medicine, Biology
• Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

BACKGROUND
Sustained virological response (SVR) after therapy with interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). We assessed the effect of SVR on HIV progression and mortality not related to liver disease.

METHODS
An observational cohort study including consecutive HIV/HCV-coinfected patients treated with interferon plus ribavirin between 2000 and 2008 in 19 centers in Spain.

RESULTS
Of 1599 patients, 626 (39%) had an SVR. After a median follow-up of approximately 5 years, we confirmed that failure to achieve an SVR was associated with an increased risk of liver-related events and liver-related death. We also observed higher rates of the following events in nonresponders than in responders: AIDS-defining conditions (rate per 100 person years, 0.84 [95% confidence interval (CI), .59-1.10] vs 0.29 [.10-.48]; P= .003), non-liver-related deaths (0.65 [.42-.87] vs 0.16 [.02-.30]; P = .002), and non-liver-related, non-AIDS-related deaths (0.55 [.34-.75] vs 0.16 [.02-.30]; P = .002). Cox regression analysis showed that the adjusted hazard ratios of new AIDS-defining conditions, non-liver-related deaths, and non-liver-related, non-AIDS-related deaths for nonresponders compared with responders were 1.90 (95% CI, .89-4.10; P = .095), 3.19 (1.21-8.40; P = .019), and 2.85 (1.07-7.60; P = .036), respectively.

CONCLUSIONS
Our findings suggest that eradication of HCV after therapy with interferon plus ribavirin in HIV/HCV-coinfected patients is associated not only with a reduction in liver-related events but also with a reduction in HIV progression and mortality not related to liver disease.